Financhill
Buy
82

WGS Quote, Financials, Valuation and Earnings

Last price:
$91.17
Seasonality move :
-19.96%
Day range:
$88.23 - $93.15
52-week range:
$25.21 - $117.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.56x
P/B ratio:
10.10x
Volume:
1.9M
Avg. volume:
947.9K
1-year change:
241.97%
Market cap:
$2.6B
Revenue:
$305.5M
EPS (TTM):
-$1.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
WGS
GeneDx Holdings
$79.8M $0.09 22.03% -86.89% $99.21
CTSO
CytoSorbents
$9M -$0.07 10.68% -41.38% $5.00
DCTH
Delcath Systems
$16.8M $0.03 194.07% -93.78% $24.08
EXAS
Exact Sciences
$688.6M -$0.10 10.52% -84.17% $68.46
ILMN
Illumina
$1B $0.94 -5.72% 430.2% $108.88
STRR
Star Equity Holdings
$16.4M -$0.25 24.23% -43.28% $8.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
WGS
GeneDx Holdings
$91.10 $99.21 $2.6B -- $0.00 0% 7.56x
CTSO
CytoSorbents
$1.23 $5.00 $77M -- $0.00 0% 1.95x
DCTH
Delcath Systems
$13.59 $24.08 $473.3M -- $0.00 0% 8.34x
EXAS
Exact Sciences
$53.65 $68.46 $10.1B -- $0.00 0% 3.52x
ILMN
Illumina
$94.79 $108.88 $15B -- $0.00 0% 3.48x
STRR
Star Equity Holdings
$2.02 $8.50 $6.5M 0.75x $0.00 0% 0.11x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
WGS
GeneDx Holdings
16.75% -0.059 2.05% 2.95x
CTSO
CytoSorbents
49.38% 0.020 22.69% 1.98x
DCTH
Delcath Systems
-- 2.956 -- 13.86x
EXAS
Exact Sciences
49.21% 1.742 28.45% 2.12x
ILMN
Illumina
45.66% 1.567 15.77% 1.34x
STRR
Star Equity Holdings
18.39% 0.331 40.47% 0.69x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
WGS
GeneDx Holdings
$58.5M -$4.6M -14.09% -17.4% -6.25% $4.1M
CTSO
CytoSorbents
$6.2M -$3.9M -58.93% -106.57% -10.01% -$3.5M
DCTH
Delcath Systems
$16.9M $642K -37.34% -40.28% 3.25% $2.1M
EXAS
Exact Sciences
$500.5M -$89.8M -19.08% -35.57% -13.04% -$365K
ILMN
Illumina
$683M $164M -20.34% -34.38% 19.89% $201M
STRR
Star Equity Holdings
$3.1M -$2.8M -13.58% -15.99% -22.03% $200K

GeneDx Holdings vs. Competitors

  • Which has Higher Returns WGS or CTSO?

    CytoSorbents has a net margin of -7.5% compared to GeneDx Holdings's net margin of -16.94%. GeneDx Holdings's return on equity of -17.4% beat CytoSorbents's return on equity of -106.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    WGS
    GeneDx Holdings
    67.13% -$0.23 $309.2M
    CTSO
    CytoSorbents
    71.13% -$0.02 $28.7M
  • What do Analysts Say About WGS or CTSO?

    GeneDx Holdings has a consensus price target of $99.21, signalling upside risk potential of 8.9%. On the other hand CytoSorbents has an analysts' consensus of $5.00 which suggests that it could grow by 306.5%. Given that CytoSorbents has higher upside potential than GeneDx Holdings, analysts believe CytoSorbents is more attractive than GeneDx Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    WGS
    GeneDx Holdings
    5 1 0
    CTSO
    CytoSorbents
    1 1 0
  • Is WGS or CTSO More Risky?

    GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CytoSorbents has a beta of 1.046, suggesting its more volatile than the S&P 500 by 4.577%.

  • Which is a Better Dividend Stock WGS or CTSO?

    GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. CytoSorbents pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios WGS or CTSO?

    GeneDx Holdings quarterly revenues are $87.1M, which are larger than CytoSorbents quarterly revenues of $8.7M. GeneDx Holdings's net income of -$6.5M is lower than CytoSorbents's net income of -$1.5M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while CytoSorbents's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 7.56x versus 1.95x for CytoSorbents. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WGS
    GeneDx Holdings
    7.56x -- $87.1M -$6.5M
    CTSO
    CytoSorbents
    1.95x -- $8.7M -$1.5M
  • Which has Higher Returns WGS or DCTH?

    Delcath Systems has a net margin of -7.5% compared to GeneDx Holdings's net margin of 5.4%. GeneDx Holdings's return on equity of -17.4% beat Delcath Systems's return on equity of -40.28%.

    Company Gross Margin Earnings Per Share Invested Capital
    WGS
    GeneDx Holdings
    67.13% -$0.23 $309.2M
    DCTH
    Delcath Systems
    85.62% $0.03 $80.2M
  • What do Analysts Say About WGS or DCTH?

    GeneDx Holdings has a consensus price target of $99.21, signalling upside risk potential of 8.9%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 77.18%. Given that Delcath Systems has higher upside potential than GeneDx Holdings, analysts believe Delcath Systems is more attractive than GeneDx Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    WGS
    GeneDx Holdings
    5 1 0
    DCTH
    Delcath Systems
    4 0 0
  • Is WGS or DCTH More Risky?

    GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.238%.

  • Which is a Better Dividend Stock WGS or DCTH?

    GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios WGS or DCTH?

    GeneDx Holdings quarterly revenues are $87.1M, which are larger than Delcath Systems quarterly revenues of $19.8M. GeneDx Holdings's net income of -$6.5M is lower than Delcath Systems's net income of $1.1M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 7.56x versus 8.34x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WGS
    GeneDx Holdings
    7.56x -- $87.1M -$6.5M
    DCTH
    Delcath Systems
    8.34x -- $19.8M $1.1M
  • Which has Higher Returns WGS or EXAS?

    Exact Sciences has a net margin of -7.5% compared to GeneDx Holdings's net margin of -14.32%. GeneDx Holdings's return on equity of -17.4% beat Exact Sciences's return on equity of -35.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    WGS
    GeneDx Holdings
    67.13% -$0.23 $309.2M
    EXAS
    Exact Sciences
    70.82% -$0.54 $4.7B
  • What do Analysts Say About WGS or EXAS?

    GeneDx Holdings has a consensus price target of $99.21, signalling upside risk potential of 8.9%. On the other hand Exact Sciences has an analysts' consensus of $68.46 which suggests that it could grow by 27.6%. Given that Exact Sciences has higher upside potential than GeneDx Holdings, analysts believe Exact Sciences is more attractive than GeneDx Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    WGS
    GeneDx Holdings
    5 1 0
    EXAS
    Exact Sciences
    18 3 0
  • Is WGS or EXAS More Risky?

    GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Exact Sciences has a beta of 0.977, suggesting its less volatile than the S&P 500 by 2.282%.

  • Which is a Better Dividend Stock WGS or EXAS?

    GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios WGS or EXAS?

    GeneDx Holdings quarterly revenues are $87.1M, which are smaller than Exact Sciences quarterly revenues of $706.8M. GeneDx Holdings's net income of -$6.5M is higher than Exact Sciences's net income of -$101.2M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 7.56x versus 3.52x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WGS
    GeneDx Holdings
    7.56x -- $87.1M -$6.5M
    EXAS
    Exact Sciences
    3.52x -- $706.8M -$101.2M
  • Which has Higher Returns WGS or ILMN?

    Illumina has a net margin of -7.5% compared to GeneDx Holdings's net margin of 12.58%. GeneDx Holdings's return on equity of -17.4% beat Illumina's return on equity of -34.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    WGS
    GeneDx Holdings
    67.13% -$0.23 $309.2M
    ILMN
    Illumina
    65.61% $0.82 $4.4B
  • What do Analysts Say About WGS or ILMN?

    GeneDx Holdings has a consensus price target of $99.21, signalling upside risk potential of 8.9%. On the other hand Illumina has an analysts' consensus of $108.88 which suggests that it could grow by 14.87%. Given that Illumina has higher upside potential than GeneDx Holdings, analysts believe Illumina is more attractive than GeneDx Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    WGS
    GeneDx Holdings
    5 1 0
    ILMN
    Illumina
    7 10 0
  • Is WGS or ILMN More Risky?

    GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Illumina has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.43%.

  • Which is a Better Dividend Stock WGS or ILMN?

    GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios WGS or ILMN?

    GeneDx Holdings quarterly revenues are $87.1M, which are smaller than Illumina quarterly revenues of $1B. GeneDx Holdings's net income of -$6.5M is lower than Illumina's net income of $131M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 7.56x versus 3.48x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WGS
    GeneDx Holdings
    7.56x -- $87.1M -$6.5M
    ILMN
    Illumina
    3.48x -- $1B $131M
  • Which has Higher Returns WGS or STRR?

    Star Equity Holdings has a net margin of -7.5% compared to GeneDx Holdings's net margin of -9.1%. GeneDx Holdings's return on equity of -17.4% beat Star Equity Holdings's return on equity of -15.99%.

    Company Gross Margin Earnings Per Share Invested Capital
    WGS
    GeneDx Holdings
    67.13% -$0.23 $309.2M
    STRR
    Star Equity Holdings
    24.27% -$0.52 $73.2M
  • What do Analysts Say About WGS or STRR?

    GeneDx Holdings has a consensus price target of $99.21, signalling upside risk potential of 8.9%. On the other hand Star Equity Holdings has an analysts' consensus of $8.50 which suggests that it could grow by 320.79%. Given that Star Equity Holdings has higher upside potential than GeneDx Holdings, analysts believe Star Equity Holdings is more attractive than GeneDx Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    WGS
    GeneDx Holdings
    5 1 0
    STRR
    Star Equity Holdings
    1 0 0
  • Is WGS or STRR More Risky?

    GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 1.002, suggesting its more volatile than the S&P 500 by 0.203%.

  • Which is a Better Dividend Stock WGS or STRR?

    GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

  • Which has Better Financial Ratios WGS or STRR?

    GeneDx Holdings quarterly revenues are $87.1M, which are larger than Star Equity Holdings quarterly revenues of $12.9M. GeneDx Holdings's net income of -$6.5M is lower than Star Equity Holdings's net income of -$1.2M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 7.56x versus 0.11x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WGS
    GeneDx Holdings
    7.56x -- $87.1M -$6.5M
    STRR
    Star Equity Holdings
    0.11x 0.75x $12.9M -$1.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Google Stock Double by 2030?
Will Google Stock Double by 2030?

If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…

Why Did David Tepper Sell NVIDIA Stock?
Why Did David Tepper Sell NVIDIA Stock?

In Q1, billionaire David Tepper of Appaloosa Management sold nearly…

Why Is Planet Labs Stock Up Today?
Why Is Planet Labs Stock Up Today?

Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 54x

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
NKE alert for Jun 28

Nike [NKE] is up 15.29% over the past day.

Buy
81
KTOS alert for Jun 28

Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.

Sell
44
GDXU alert for Jun 28

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock